Johnson and Johnson is seeking to sell its manufacturer of active pharmaceutical ingredients, Noramco, in a move that could value the division at as much as $800 million, according to people familiar with the matter.
Noramco is attracting interest primarily from buyout firms, the people said this week. The unit has annual earnings before interest, taxes, depreciation and amortization of more than $70 million, some of the people added.
The sources asked not to be identified because the deliberations are confidential.
Representatives of Johnson & Johnson declined to comment.
Noramco manufactures the active ingredients in painkillers, including oxycodone.
Pharmaceutical M&A had its strongest year in history in 2015, and is expected to continue at a robust pace despite headwinds, including choppier valuations in the biotech space and unsteady credit markets.
(Reporting by Greg Roumeliotis and Carl O’Donnell in New York; Editing by Sandra Maler)
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
